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What is already known on this topic?
 ► Neonatal seizures are difficult to detect 
clinically, and interpretation of the neonatal 
electroencephalography (EEG) is a highly 
specialised skill.
 ► The seizure burden is often high, particularly 
in neonates with hypoxic-ischaemic 
encephalopathy or stroke.
What this study adds?
 ► This is the first European-wide examination of 
continuous EEG monitoring of neonatal seizures 
in a large cohort.
 ► This multicentre EEG study showed that 
critically ill neonates sustain a high burden of 
seizures.
 ► Both underdiagnosis and overdiagnosis of 
seizures was common, despite availability of 
continuous EEG monitoring.
 ► When antiepileptic drugs were given, only 11% 
were given within 1 hour of the electrographic 
seizure episode occurring.
AbsTrACT
Objective The aim of this multicentre study was 
to describe detailed characteristics of electrographic 
seizures in a cohort of neonates monitored with 
multichannel continuous electroencephalography (cEEG) 
in 6 European centres.
Methods Neonates of at least 36 weeks of gestation 
who required cEEG monitoring for clinical concerns were 
eligible, and were enrolled prospectively over 2 years 
from June 2013. Additional retrospective data were 
available from two centres for January 2011 to February 
2014. Clinical data and EEGs were reviewed by expert 
neurophysiologists through a central server.
results Of 214 neonates who had recordings suitable 
for analysis, EEG seizures were confirmed in 75 (35%). 
The most common cause was hypoxic-ischaemic 
encephalopathy (44/75, 59%), followed by metabolic/
genetic disorders (16/75, 21%) and stroke (10/75, 13%). 
The median number of seizures was 24 (IQR 9–51), and 
the median maximum hourly seizure burden in minutes 
per hour (MSB) was 21 min (IQR 11–32), with 21 (28%) 
having status epilepticus defined as MSB>30 min/hour. 
MSB developed later in neonates with a metabolic/
genetic disorder. Over half (112/214, 52%) of the 
neonates were given at least one antiepileptic drug 
(AED) and both overtreatment and undertreatment 
was evident. When EEG monitoring was ongoing, 
27 neonates (19%) with no electrographic seizures 
received AEDs. Fourteen neonates (19%) who did have 
electrographic seizures during cEEG monitoring did not 
receive an AED.
Conclusions Our results show that even with access to 
cEEG monitoring, neonatal seizures are frequent, difficult 
to recognise and difficult to treat.
Oberservation study number NCT02160171
InTrOduCTIOn
Substantial technological advances have facilitated 
prolonged continuous electroencephalography 
(cEEG) recording, but the diagnosis and manage-
ment of neonatal seizures remains challenging. 
Interpretation of the neonatal EEG is a highly 
specialised skill. Very few neonatal units have rapid 
access to expert neurophysiology opinion, although 
the majority have equipment suitable for amplitude 
integrated EEG (aEEG) or cEEG monitoring.1 In 
future, automated seizure detection should inform 
clinical decision making and reduce the time 
required for experts to review long recordings.2 
Prolonged cEEG recordings have confirmed the 
extent of the mismatch between clinical seizures 
and the electrographic seizure burden,3 and have 
revealed the true extent of the seizure burden 
present in many neurologically sick neonates. cEEG 
is currently recommended by the American Clinical 
Neurophysiology Society for neonates.4 A recent 
multicentre cEEG study in the USA found that 59% 
of neonates with clinically suspected seizures who 
were monitored for at least 24 hours had more 
than seven seizures, and 16% developed status 
epilepticus (SE).5 
The subtle nature of clinical seizures in neonates 
leads to both overdiagnosis and under-recognition. 
The problem of ‘clinically silent’ or ‘electrographic 
only’ seizures (electroclinical dissociation) is 
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Figure 1 Flow diagram of recruitment, seizures and antiepileptic drug (AED) use in the cohort. EEG, electroencephalography.
particularly prevalent in this age group. The mismatch increases 
after the administration of antiepileptic drugs, when it has 
been termed ‘uncoupling’.6 Current estimates suggest that the 
mortality among neonates with seizures is around 10%, and 50% 
of those who survive have a significant disability.7 8 The debate 
regarding whether or not to treat to electrographic seizure quies-
cence, and whether achieving this would improve the prognosis, 
continues.9 10 Treatment on the basis of clinical diagnosis alone 
is the current standard of care in many neonatal units, but this 
policy carries risks. Undertreatment may lead to ‘kindling’ of 
additional seizures, adding to any pre-existing brain injury, and 
permanently altering seizure thresholds in the brain.11 On the 
other hand, overtreatment of neonates with antiepileptic drugs 
carries the risk of using neurotoxic medications, prolonging 
intensive care (with associated costs and parental separation) and 
exposing the newborn to potential complications from intensive 
care procedures or sedation.
The aim of this multicentre study was to describe detailed 
characteristics of electrographic seizures in a large cohort of term 
neonates in Europe monitored with cEEG. A secondary aim was 
to establish how and when seizures were treated during cEEG 
monitoring. We also aimed to establish a European network with 
shared definitions and a common platform for EEG and data 
collection, in order to facilitate future collaborative multicentre 
research in this important area.
MeThOds
study design and participants
This was a multicentre study in six neonatal intensive care 
units (NICUs) across four European countries (Ireland, 
The Netherlands, Sweden, the UK). All neonates of at least 
36 weeks gestation who required EEG monitoring for clin-
ical purposes (including neonatal encephalopathy, suspected 
stroke, intracranial infection and unusual movement patterns) 
were eligible for inclusion in the study. Retrospective data were 
available from two sites for neonates enrolled between January 
2011 and February 2014. Prospective data were collected from 
all six sites with enrolment between June 2013 and June 2015. 
Neonates with <6 hours of good-quality EEG recording were 
excluded. Written informed consent was obtained from at least 
one parent/guardian.
At each centre, clinical data for each neonate were entered 
online using a secure database system designed specifically for 
this study (MedSciNet, Stockholm, Sweden) by the local investi-
gator, research fellow or research nurse. Clinical data collected 
included delivery details, information on the neonatal course 
and final primary diagnosis. The timing and types of antiepi-
leptic drugs (AEDs) administered, if any, were also recorded.
eeG recording and analysis
All neonates were monitored with cEEG (NicoletOne ICU 
Monitor &  Xltek EEG, Natus, USA or Nihon Kohden Neurofax 
EEG-1200, Japan). cEEG monitoring commenced as soon as 
possible after birth and was continued for up to 72 hours where 
possible. Multichannel EEG recordings were obtained with 
active electrodes located at F3, F4, C3, C4, T3, T4, O1, O2 
(or P3 and P4) and Cz, according to the international 10–20 
system adjusted for neonates, with single channel electrocardi-
ography and respiration monitoring if possible. The aEEG signal 
was also displayed simultaneously, usually with two channels. All 
recognised seizures in the cohort were treated when diagnosed, 
as per routine practice, whether this was on the basis of a clin-
ical diagnosis or a diagnosis with aEEG or cEEG. We did not 
have a standard protocol for review of cEEG at any site during 
this study. Neonatologists primarily used the aEEG display to 
aid seizure treatment decisions when necessary. Immediate 
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Table 1 Characteristics of neonates, n=214*
Median (IQr)*
Gestational age at delivery (weeks) 40 (39–41)
Birth weight (g) 3435 (3110–3803)
Sex: n (%)
  Male 137 (64.0)
  Female 77 (36.0)
Apgar score at 5 min (n=209) 5 (3–8)
Requirement for EEG monitoring: n (%)
  HIE 107 (50.0)
  Clinician request 67 (31.3)
  Stroke 7 (3.3)
  Infectious 4 (1.9)
  Metabolic 3 (1.4)
  Other 26 (12.1)
Baby developed HIE: n (%)
  Yes 141 (65.9)
  No 73 (34.1)
Clinical Sarnat score at 24 hours (n=132): n (%)
  Mild 51 (38.6)
  Moderate 57 (43.2)
  Severe 24 (18.2)
Therapeutic hypothermia: n (%)
  Cooled 106 (49.5)
  Uncooled 108 (50.5)
Final diagnosis: n (%)
  HIE grade
   Mild 50 (23.4)
   Moderate† 59 (27.6)
   Severe 24 (11.2)
  Metabolic/genetic disorder‡ 20 (9.3)
  Stroke§ 18 (8.4)
  Suspected seizures—unconfirmed 12 (5.6)
  Perinatal asphyxia without clinical encephalopathy 7 (3.3)
  Sepsis/meningitis 6 (2.8)
  Intracranial haemorrhage 5 (2.3)
  Other¶ 13 (6.1)
*Unless otherwise stated.
†n=1 had meningitis also.
‡n=1 had severe HIE also. 
§n=2 had mild HIE and n=3 had moderate HIE also.
¶n=3 for postnatal cardiorespiratory arrest (n=1 with mild HIE also, n=1 
with severe HIE also); n=2  for   each of: neonatal drug withdrawal syndrome; 
respiratory distress; seizures of unknown origin; n=1 for each of: congenital 
anaemia; congenital  brain malformation; meconium aspiration syndrome; 
tracheo-oesphageal atresia and cystic periventricular leukomalacia  periventricular 
leukomalacia. 
 EEG, electroencephalography; HIE, hypoxic-ischaemic encephalopathy.
cEEG interpretation was not always available, but, in the case 
of suspected seizures on aEEG or clinical seizures, the cEEG was 
interpreted by local neurophysiologists when available.
Local protocols for AED administration were used at each 
site; however, the timing of AED administration in relation to 
seizure onset is never stipulated. This is largely due to the fact 
that detailed EEG seizure information has never been available 
before.
seizure analysis and quantification
Clinical seizures were recorded in the medical and nursing notes 
and seizure charts according to routine local practice. At the end 
of the EEG recording, EEGs were uploaded through an elec-
tronic case report form to a central EEG review server. cEEG 
recordings were reviewed in their entirety and all seizures were 
annotated by one member of a group 4 board-certified elec-
troencephalographers, with specific expertise in neonatal EEG 
(GBB, SM, KVH, EP). For any difficult cases where some uncer-
tainty existed (very few), a consensus was reached between two 
reviewers. All reviewers used a standard protocol for seizure 
annotation. An electrographic seizure was defined as a sudden 
repetitive, stereotyped discharge of minimum 10 s duration on 
one or more EEG channels with evolving frequency, amplitude 
and morphology.12 Following this analysis, summary measures of 
seizures over different time scales were calculated. The seizure 
period was defined as the time from the start of the first recorded 
seizure to the end of the last recorded seizure. Within this period, 
the total duration of all seizures (total seizure burden (TSB)) was 
calculated. The number of seizures and median seizure dura-
tion were also calculated. The maximum hourly seizure burden 
(maximum seizure burden (MSB)) in minutes per hour and the 
time of MSB (hours after birth) was calculated using a 1 hour 
window, shifted across the EEG monitoring period with a 1 min 
interval. SE was defined as MSB≥30 min/hour.13
seizure treatment analysis
The type, dose and timing of every AED administered to each 
neonate was recorded. For the purposes of assessing seizure 
treatment, seizures recorded on the EEG with at least 2 hours 
between them were considered to be separate seizure episodes. 
Therefore, in each EEG we created segments of the EEG called 
seizure episodes. These seizure episodes were of varying duration 
as the only criteria for a seizure episode was that it contained 
ongoing seizure activity with no interval longer than 2 hours.
Administration of an AED within 60 min of the start of the 
seizure episode was considered appropriate for the purposes 
of treatment analysis in this study. We would anticipate that a 
seizure episode should be treated within 1 hour of onset if the 
seizures were recognised. There are no national or international 
guidelines outlining how soon seizures should be treated. This 
is largely because until recently it was very hard to accurately 
identify electrographic seizures and we know that clinical recog-
nition is inaccurate.
statistical analysis
Continuous variables were described using median and IQR 
and categorical variables using frequency and percentage. A 
one-sample binomial test was used to compare the propor-
tions of male and female neonates in our study. Differences in 
seizure characteristics between the final diagnosis groups were 
investigated using the Kruskal-Wallis test. When a statistically 
significant difference was found, pairwise comparisons were 
performed using Dunn’s procedure with a Bonferroni correction 
for multiple comparisons. A Χ2 test was used to compare propor-
tions between groups. Statistical analysis was performed using 
IBM SPSS Statistics (V.22.0; IBM, Armonk, New York, USA). All 
tests were two-sided and a p value <0.05 was considered to be 
statistically significant.
resulTs
study sample
Across the six sites, a total of 240 neonates were eligible and 
consented to participate in the study (53 from the retrospective 
cohort and 187 from the prospective cohort, figure 1). During 
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Table 2 Aetiology by seizure status group, n=214
n
seizures on eeG
no seizures on eeG 
did not receive Aed before 
eeG start (n=115) 
received Aed before eeG start 
(n=24) 
n (%) n (%) n (%)
HIE grade
  Mild 50 0 (0.0) 48 (41.7) 2 (8.3)
  Moderate 59 27 (36.0) 23 (20.0) 9 (37.5)
  Severe 24 17 (22.7) 3 (2.6) 4 (16.7)
Metabolic/genetic disorder 20 16 (21.3) 4 (3.5) 0 (0.0)
Stroke 18 10 (13.3) 5 (4.3) 3 (12.5)
Suspected seizures—unconfirmed 12 0 (0.0) 9 (7.8) 3 (12.5)
Perinatal asphyxia without clinical encephalopathy 7 0 (0.0) 7 (6.1) 0 (0.0)
Sepsis/meningitis 6 2 (2.7) 3 (2.6) 1 (4.2)
Intracranial haemorrhage 5 0 (0.0) 4 (3.5) 1 (4.2)
Other 13 3 (4.0) 9 (7.8) 1 (4.2)
the study period, all eligible infants were approached where 
appropriate. 
Twenty-six infants were excluded from the 240 neonates 
eligible for this study: 2 neonates had no EEG recording avail-
able (data lost); 21 neonates had <6 hours of recording and 3 
neonates had poor quality recordings. No neonates were with-
drawn or died during the study period. Hence, 214 neonates 
were included in the study analysis (50 from the retrospective 
study and 164 from the prospective study) . The retrospective 
and prospective cohorts did not differ in terms of gestational 
age, birth weight or sex. The percentage of neonates with hypox-
ic-ischaemic encephalopathy (HIE) (any grade) was slightly 
higher in the retrospective cohort compared with the prospec-
tive cohort, but the difference was not statistically significant 
(76% vs 63%, p=0.085).
The most common reason for clinician requested EEG moni-
toring was HIE. Over 60% (133/214, 62%) of neonates had a 
primary diagnosis of HIE with 50 graded as mild, 59 as moderate 
and 24 as severe (table 1). A metabolic/genetic disorder was 
the second most common diagnosis (n=20, 9%), followed by 
stroke (n=18, 8%), clinically suspected seizures (n=12, 6%) and 
perinatal asphyxia without clinical encephalopathy (n=7, 3%). 
Almost three-quarters (97/133, 73%) of neonates with HIE as 
their final diagnosis were treated with therapeutic hypothermia 
(21/50 mild HIE; 52/59 moderate HIE; 24/24 severe HIE).
The characteristics of the 214 neonates included in the anal-
ysis are described in table 1. A higher percentage of neonates 
were male (64% male vs 36% female, p<0.001).
eeG monitoring and seizure characteristics
EEG monitoring commenced at a median age of 8.2 hours of 
age (IQR 4.0–29.7) and continued for a median of 70.3 hours 
(IQR 31.0–95.7). Monitoring continued for at least 24 hours 
for the majority of neonates (173/214, 81%). Over one-third 
(75/214, 35%) of neonates had at least one electrographic 
seizure identified by the expert group. Once monitored, males 
and females were equally likely to have seizures identified; (34% 
(47/137) for males vs 36% (28/77) for females, p=0.762). The 
principle diagnosis of the neonates with and without seizures 
is described in table 2. Of the 59 neonates with moderate HIE, 
27 (46%) had seizures while 17 of the 24 (71%) neonates with 
severe HIE had seizures. There were also relatively high number 
of neonates with metabolic/genetic disorders (16/20, 80%) and 
stroke (10/18, 56%) who had seizures. Six neonates had ongoing 
electrographic seizures at the start of EEG monitoring, and in 
this group the EEG and study enrolment tended to be late—at 
a median age of 19.8 hours (IQR 6.7–55.8). Of those, three had 
a diagnosis of stroke, two HIE (one with stroke and moderate 
HIE) and one had a metabolic/genetic disorder.
The characteristics of the seizures according to the underlying 
diagnosis are described in table 3. The median period between 
the start of the first recorded seizure to the end of the last 
recorded seizure ‘seizure period’ was 15.9 hours (IQR 4.4–42.1). 
A statistically significant difference was not found across the 
diagnostic groups for seizure period, although seizures tended to 
persist longer in neonates with severe HIE (table 3).
The median age at the time of the first recorded EEG seizure 
was 19.4 hours (IQR 12.8–48.8). Age at first recorded seizure 
differed by aetiology (p=0.001). Neonates with a metabolic/
genetic disorder were significantly older at first recorded seizure 
than both neonates with moderate (adjusted p=0.002) and 
severe HIE (adjusted p=0.002).
The median length of time from commencement of EEG to 
identification of first seizure was 6.0 hours (IQR 1.4–14.6). The 
time at which the first seizure was seen did not differ significantly 
(p=0.364) between the group who had been exposed to AEDs 
prior to the commencement of monitoring (median (IQR): 5.4 
(1.9–28.9) hours, n=23) and those who had not (median (IQR): 
6.0 (1.2–12.5) hours, n=52).
TSB ranged from 29 s to 15.18 hours with a median (IQR) of 
68.5 (27.5–166.8) min. TSB was highest for neonates with stroke 
or severe HIE, but a statistically significant difference was not 
found between aetiologies (p=0.060). The number of seizures 
identified per neonate ranged from 1 to 551 with a median 
of 24 (IQR 9–51). Number of seizures differed by aetiology 
(p=0.005). Neonates with moderate HIE had significantly fewer 
recorded seizures than both neonates with severe HIE (adjusted 
p=0.034) and neonates with stroke (adjusted p=0.019). The 
median seizure duration was 109 s (IQR 65–225.5). Median 
seizure duration was not significantly different between different 
aetiologies (p=0.069).
MSB occurred at a median of 31 hours (IQR 17–61) after birth 
and was significantly different between aetiologies (p=0.002). 
MSB occurred significantly later for neonates with a metabolic/
genetic disorder compared with neonates with moderate HIE 
(adjusted p=0.001). MSB ranged from 29 s/hour to 60 min/hour 
with a median (IQR) of 21.3 min/hour (11.3–32.3). Although 
MSB was highest for neonates with stroke or severe HIE, a 
F497Rennie JM, et al. Arch Dis Child Fetal Neonatal Ed 2019;104:F493–F501. doi:10.1136/archdischild-2018-315624
Original article
Ta
bl
e 
3 
Se
iz
ur
e 
ch
ar
ac
te
ris
tic
s 
by
 a
et
io
lo
gy
, n
=
75
A
ll 
se
iz
ur
e 
ba
bi
es
 
(n
=
75
)
M
od
er
at
e 
h
Ie
 (n
=
27
)
se
ve
re
 h
Ie
 (n
=
17
)
M
et
ab
ol
ic
/g
en
et
ic
 
di
so
rd
er
 (n
=
16
)
st
ro
ke
 (n
=
10
)
O
th
er
* 
(n
=
5)
P 
va
lu
es
†
M
ed
ia
n 
(IQ
r)
M
ed
ia
n 
(IQ
r)
M
ed
ia
n 
(IQ
r)
M
ed
ia
n 
(IQ
r)
M
ed
ia
n 
(IQ
r)
M
ed
ia
n 
(IQ
r)
Se
iz
ur
e 
pe
rio
d 
(h
ou
rs
)‡
15
.9
 (4
.4
 to
 4
2.
1)
8.
7 
(2
.0
 to
 2
1.
2)
33
.5
 (1
1.
9 
to
 5
8.
0)
25
.0
 (1
.1
 to
 7
7.
6)
22
.1
 (6
.6
 to
 5
5.
1)
14
.1
 (4
.0
 to
 6
5.
6)
0.
06
8
Ag
e 
(h
ou
rs
 a
fte
r b
irt
h)
 a
t fi
rs
t r
ec
or
de
d 
se
iz
ur
e
19
.4
 (1
2.
8 
to
 4
8.
8)
16
.5
 (8
.7
 to
 3
5.
5)
15
.2
 (1
1.
0 
to
 2
0.
7)
56
.6
 (4
2.
7 
to
 9
9.
3)
25
.4
 (1
4.
2 
to
 4
4.
9)
31
.8
 (1
8.
1 
to
 7
4.
4)
0.
00
1§
To
ta
l s
ei
zu
re
 b
ur
de
n 
(m
in
)
68
.5
 (2
7.
5 
to
 1
66
.8
)
48
.5
 (2
3.
2 
to
 7
9.
6)
11
2.
8 
(3
2.
7 
to
 2
23
.6
)
39
.9
 (1
4.
6 
to
 2
10
.6
)
14
9.
6 
(5
4.
2 
to
 2
89
.6
)
11
7.
3 
(2
.9
 to
 2
83
.6
)
0.
06
0
N
um
be
r o
f s
ei
zu
re
s
24
.0
 (9
.0
 to
 5
1.
0)
10
.0
 (4
.0
 to
 3
2.
0)
31
.0
 (2
1.
0 
to
 5
7.
5)
30
.5
 (7
.0
 to
 5
6.
8)
50
.0
 (1
5.
0 
to
 1
66
.5
)
12
.0
 (2
.0
 to
 2
10
.0
)
0.
00
5¶
M
ed
ia
n 
se
iz
ur
e 
du
ra
tio
n 
(s
)
10
9.
0 
(6
5.
0 
to
 2
25
.5
)
14
3.
0 
(9
6.
0 
to
 6
96
.0
)
10
9.
0 
(6
6.
5 
to
 2
05
.8
)
93
.8
 (4
4.
1 
to
 1
62
.6
)
10
4.
0 
(6
3.
1 
to
 1
58
.0
)
70
.0
 (4
2.
0 
to
 2
43
.0
)
0.
06
9
M
ax
im
um
 h
ou
rly
 s
ei
zu
re
 b
ur
de
n 
(M
SB
) (
m
in
/h
ou
r)
21
.3
 (1
1.
3 
to
 3
2.
3)
18
.0
 (1
4.
4 
to
 2
8.
3)
24
.7
 (1
4.
2 
to
 4
0.
1)
13
.4
 (7
.9
 to
 2
4.
2)
30
.3
 (1
8.
3 
to
 4
2.
9)
20
.7
 (1
.3
 to
 3
0.
2)
0.
06
3
Ho
ur
 a
fte
r b
irt
h 
in
 w
hi
ch
 M
SB
 o
cc
ur
re
d
31
.0
 (1
7.
0 
to
 6
1.
0)
17
.0
 (1
2.
0 
to
 4
3.
0)
27
.0
 (1
8.
5 
to
 4
9.
0)
57
.0
 (4
3.
8 
to
 1
45
.5
)
29
.5
 (2
0.
8 
to
 6
5.
0)
56
.0
 (2
9.
5 
to
 1
02
.0
)
0.
00
2*
*
Ag
e 
(h
ou
rs
 a
fte
r b
irt
h)
 a
t l
as
t r
ec
or
de
d 
se
iz
ur
e
55
.2
 (2
8.
5 
to
 8
6.
1)
34
.4
 (1
6.
6 
to
 5
9.
9)
54
.3
 (2
8.
1 
to
 8
0.
3)
71
.9
 (4
7.
9 
to
 3
04
.9
)
58
.4
 (3
1.
5 
to
 1
22
.0
)
56
.6
 (3
0.
2 
to
 1
26
.5
)
0.
00
8†
†
*n
=
2 
fo
r s
ei
zu
re
s 
of
 u
nk
no
w
n 
or
ig
in
; n
=
2 
fo
r s
ep
si
s/
m
en
in
gi
tis
; n
=
1 
fo
r p
os
tn
at
al
 c
ar
di
or
es
pi
ra
to
ry
 a
rr
es
t (
an
d 
se
ve
re
 H
IE
).
†F
ro
m
 K
ru
sk
al
l-W
al
lis
 te
st
, w
ith
 ‘o
th
er
’ e
xc
lu
de
d 
fro
m
 th
e 
an
al
ys
is.
‡T
im
e 
fro
m
 s
ta
rt
 o
f fi
rs
t E
EG
 s
ei
zu
re
 to
 e
nd
 o
f l
as
t E
EG
 s
ei
zu
re
.
§P
ai
rw
is
e 
co
m
pa
ris
on
s 
re
ve
al
ed
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
be
tw
ee
n 
th
e 
m
et
ab
ol
ic
/g
en
et
ic
 d
is
or
de
r g
ro
up
 a
nd
 b
ot
h 
th
e 
m
od
er
at
e 
HI
E 
(a
dj
us
te
d 
p=
0.
00
2)
 a
nd
 th
e 
se
ve
re
 H
IE
 (a
dj
us
te
d 
p=
0.
00
2)
 g
ro
up
s.
¶P
ai
rw
is
e 
co
m
pa
ris
on
s 
re
ve
al
ed
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
be
tw
ee
n 
th
e 
m
od
er
at
e 
HI
E 
gr
ou
p 
an
d 
bo
th
 th
e 
se
ve
re
 H
IE
 (a
dj
us
te
d 
p=
0.
03
4)
 a
nd
 th
e 
st
ro
ke
 (a
dj
us
te
d 
p=
0.
01
9)
 g
ro
up
s.
**
Pa
irw
is
e 
co
m
pa
ris
on
s 
re
ve
al
ed
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
be
tw
ee
n 
th
e 
m
et
ab
ol
ic
/g
en
et
ic
 d
is
or
de
r g
ro
up
 a
nd
 th
e 
m
od
er
at
e 
HI
E 
gr
ou
p 
(a
dj
us
te
d 
p=
0.
00
1)
.
††
Pa
irw
is
e 
co
m
pa
ris
on
s 
re
ve
al
ed
 s
ig
ni
fic
an
t d
iff
er
en
ce
s 
be
tw
ee
n 
th
e 
m
et
ab
ol
ic
/g
en
et
ic
 d
is
or
de
r g
ro
up
 a
nd
 th
e 
m
od
er
at
e 
HI
E 
gr
ou
p 
(a
dj
us
te
d 
p=
0.
00
5)
.
EE
G,
 e
le
ct
ro
en
ce
ph
al
og
ra
ph
y;
 H
IE
, h
yp
ox
ic
-is
ch
ae
m
ic
 e
nc
ep
ha
lo
pa
th
y.
 
significant difference was not found for aetiology (p=0.063). 
Twenty-one neonates with seizures (28%) had SE (MSB≥30 min/
hour).13 The aetiology of neonates with SE was as follows: 
severe HIE (n=7), moderate HIE (n=6), stroke (n=5, two with 
concomitant moderate HIE), metabolic/genetic disorder (n=2) 
and sepsis/meningitis (n=1). The last electrographic seizure was 
recorded at a median age of 55.2 hours (IQR 28.5–86.1) and was 
significantly different between final diagnosis groups (p=0.008). 
Neonates with a metabolic/genetic disorder were significantly 
older at last recorded seizure than neonates with moderate HIE 
(adjusted p=0.005).
seizure treatment
Over half (112/214, 52%) of the neonates were given at least 
one AED, administered at a median of 12.2 hours of age (IQR 
5.5–37.5). Almost all (104/112, 93%) received phenobarbitone 
as their first-line treatment (dosage: 20 mg/kg for n=93 and 
10 mg/kg for n=11), with the remaining eight receiving midaz-
olam (n=4), lidocaine (n=2), levetiracetam (n=1) and paralde-
hyde (n=1). Forty-seven of the 112 neonates (42%) received 
their first AED before EEG monitoring commenced (median 
(IQR): 5 hours (2.7–13.5)). Twenty-one of these 47 neonates 
(45%) were treated before transfer to the monitoring centres 
and hence were treated on clinical suspicion of seizure. Two of 
these 47 neonates were treated on the basis of seizure recog-
nition on aEEG (applied before full cEEG available). Neonates 
with EEG confirmed seizures were more likely to have received 
an AED before EEG monitoring commenced (23/75 (31%) vs 
24/139 (17%), p=0.024). Of the 65 neonates who received their 
first AED after EEG monitoring commenced, the median time 
from EEG start to first AED was 5.0 hours (IQR 2.1–16.6).
Neonates without electrographic seizures
In total, 139 neonates did not have any recorded electrographic 
seizures. Of these, almost one-third (44/139, 32%) were admin-
istered an AED (table 4). The clinical diagnoses of these neonates 
were: moderate HIE (n=21), severe HIE (n=6), stroke (n=5), 
intracranial haemorrhage (n=4), mild HIE (n=3), suspected 
seizures—unconfirmed (n=3), sepsis/meningitis (n=1) and 
postnatal cardiorespiratory arrest/mild HIE (n=1). The median 
age at which they received their first AED was 10.9 hours (IQR 
4.1–38.3 hours). The majority (33/44, 75%) received one type 
of AED, while nine neonates (20%) received two AEDs and two 
neonates (5%) received three AEDs. Over half (24/44, 55%) of 
these neonates received their first AED before EEG monitoring 
commenced. Twenty-seven neonates who did not have any 
electrographic seizures received an AED after EEG monitoring 
commenced, including seven neonates who had also received an 
AED before the start of EEG monitoring. A total of 42 loading 
doses were given to the 27 neonates after EEG commencement, 
and the indications for AED use were: clinical seizure (n=29), 
suspected seizures (n=6), EEG seizure (n=2), aEEG seizure 
(n=1) and unknown (n=4). We do not know if the EEG was 
misinterpreted in these cases or simply not used. However, only 
one EEG had a rhythmic artefact present due to prominent respi-
ration that may have been misinterpreted as a seizure.
Neonates with electrographic seizures
The majority of neonates (61/75, 81%) with electrographic 
seizures were administered an AED during EEG monitoring 
(table 5). Seven neonates never received an AED at any time, 
while an additional seven received an AED before commence-
ment of the EEG only and subsequent seizures were not treated. 
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Table 4 Neonates without electrographic seizures on the EEG, n=139
never received 
Aed (n=95)
received Aed at any 
time (n=44) 
received Aed 
before start of eeG 
monitoring (n=24) 
received Aed after start of 
eeG monitoring (n=27)* 
n (%) n (%) n (%) n (%)
Final diagnosis
  HIE grade
   Mild 47 (49.5) 3 (6.8) 2 (8.3) 1 (3.7)
   Moderate 11 (11.6) 21 (47.7) 9 (37.5) 15 (55.6)
   Severe 1 (1.1) 6 (13.6) 4 (16.7) 3 (11.1)
  Metabolic/genetic disorder 4 (4.2) 0 (0.0)
  Stroke 3 (3.2) 5 (11.4) 3 (12.5) 4 (14.8)
  Suspected seizures—unconfirmed 9 (9.5) 3 (6.8) 3 (12.5) 1 (3.7)
  Sepsis/meningitis 3 (3.2) 1 (2.3) 1 (4.2) 0 (0.0)
  Intracranial haemorrhage 1 (1.1) 4 (9.1) 1 (4.2) 3 (11.1)
  Perinatal asphyxia without clinical encephalopathy 7 (7.4) 0 (0.0)
  Other 9 (9.5) 1 (2.3) 1 (4.2) 0 (0.0)
Type of AED†
  Phenobarbital 42 (95.5) 22 (91.7) 25 (92.6)
  Midazolam 7 (15.9) 3 (12.5) 4 (14.8)
  Phenytoin 3 (6.8) 3 (12.5) 0 (0.0)
Liddocaine 2 (4.5) 0 (0.0) 2 (7.4)
  Clonazepam 2 (4.5) 2 (8.3) 0 (0.0)
  Bumetanide 1 (2.3) 0 (0.0) 1 (3.7)
Number of types of AEDs administered†
  1 33 (75.0) 19 (79.2) 23 (85.2)
  2 9 (20.5) 4 (16.7) 3 (11.1)
  3 2 (4.5) 1 (4.2) 1 (3.7)
*Includes seven neonates who also received AED before start of EEG monitoring.
†For neonates who were administered an AED.
AED, antiepileptic drug; EEG, electroencephalography; HIE, hypoxic-ischaemic encephalopathy.
TSB, MSB and number of seizures were significantly higher in 
the seizure neonates who received an AED during EEG moni-
toring (n=61) compared with seizure neonates who did not 
(n=14). The seizure period was also significantly longer in the 
group that received an AED (table 6). The TSB in the group with 
seizures which were not treated during the recording (n=14) 
ranged from 29 s to 4 hours and 47 min with a median (IQR) 
of 33.2 (1.2–104.4) min. A review of all the seizures in these 
14 babies revealed that the vast majority of seizures were low 
amplitude on the EEG and showed little or no change on the 
aEEG. It follows, that if the local practice was to use aEEG to 
screen for areas of EEG interest to review, these seizures would 
have been missed.
The median age at first AED was 13.0 hours (IQR 7.6–37.2). 
The majority (51/68, 75%) received either one or two types of 
AED. Almost all neonates were administered phenobarbitone 
as their first-line treatment (65/68, 96%; dosage: 20 mg/kg for 
n=55 and 10 mg/kg for n=10).
One-third (23/68, 34%) of neonates with electrographic 
seizures who were administered an AED received it before 
EEG monitoring commenced. Sixty-one of the 68 neonates 
with electrographic seizures received an AED after EEG moni-
toring commenced, including 16 neonates who also received 
AED before the start of the EEG monitoring. The number of 
different AED medications received after EEG commencement 
ranged from 1 to 6 with a median of 2 (IQR 1–3). Of the 45 
seizure neonates who received their first AED after EEG moni-
toring commenced, 8 received it before the first recorded seizure 
and the remaining 37 neonates received it at a median time of 
2.0 hours (IQR 0.8–4.2) after their first recorded seizure.
Across the 75 neonates with seizures, a total of 221 seizure 
episodes occurred and 11% (24/221) were treated with an AED 
within 60 min of the start of the seizure episode. The number of 
seizure episodes ranged from 1 to 14 with a median of 2 (IQR 
1–4). Fifty-four (72%) neonates with seizures (median number 
of seizure episodes 2 (IQR 1–4), range 1–14) did not receive 
an AED at the appropriate time for any seizure episode, seven 
of whom did not receive an AED at any time. Seven (out of 25) 
neonates with a single seizure episode had that episode treated 
appropriately. Fourteen neonates with more than one seizure 
episode had at least one episode treated appropriately, with the 
percentage of seizure episodes appropriately treated ranging 
from 17% to 67% with a median (IQR) of 33% (24%–50%), 
figure 2. When we examined each entire seizure episode, 39% 
(86/221) were treated with an AED at some point during the 
episode or within 60 min of the end of the seizure episode.
dIsCussIOn
The findings of this study reflect current practice in European 
neonatal units that have access to cEEG monitoring. In neonates 
in whom EEG monitoring was clinically required, electrographic 
seizures were present in over a third. Accurate quantification of 
the number and duration of electrographic seizures by expert 
reviewers revealed the high seizure burden in many cases, even 
in spite of treatment. Seizures were generally seen after about 
6 hours of recording when present. In neonates with HIE, 
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Table 5 AEDs administered to neonates with electrographic seizures on the EEG, n=75
never received 
Aed (n=7)
received Aed at any 
time (n=68)
received Aed before start of 
eeG monitoring (n=23)
received Aed after start of 
eeG monitoring (n=61)*
n (%) n (%) n (%) n (%)
Final diagnosis
  HIE grade
   Moderate 4 (57.1) 23 (33.8) 9 (39.1) 18 (29.5)
   Severe 1 (14.3) 16 (23.5) 4 (17.4) 16 (26.2)
  Metabolic/genetic disorder 1 (14.3) 15 (22.1) 5 (21.7) 14 (23.0)
  Stroke 0 (0.0) 10 (14.7) 2 (8.7) 10 (16.4)
  Sepsis/meningitis 0 (0.0) 2 (2.9) 2 (8.7) 2 (3.3)
  Other 1 (14.3) 2 (2.9) 1 (4.3) 1 (1.6)
Type of AED†
  Phenobarbital 65 (95.6) 23 (100.0) 56 (91.8)
  Midazolam 19 (27.9) 1 (4.3) 18 (29.5)
  Phenytoin 25 (36.8) 1 (4.3) 24 (39.3)
Lidocaine 6 (8.8) 1 (4.3) 5 (8.2)
  Clonazepam 5 (7.4) 1 (4.3) 4 (6.6)
  Keppra/levetiracetam 3 (4.4) 0 (0.0) 3 (4.9)
  Paraldehyde 4 (5.9) 0 (0.0) 4 (6.6)
  Bumetanide 3 (4.4) 0 (0.0) 3 (4.9)
  Pyridoxal 5 phosphate 2 (2.9) 0 (0.0) 2 (3.3)
  Pyridoxin 3 (4.4) 0 (0.0) 3 (4.9)
  Vigabatrin 2 (2.9) 0 (0.0) 2 (3.3)
Number of types of AEDs administered†
  1 23 (33.8) 19 (82.6) 20 (32.8)
  2 28 (41.2) 4 (17.4) 25 (41.0)
  3 12 (17.6) 0 (0.0) 12 (19.7)
  ≥4 5 (7.4) 0 (0.0) 4 (6.6)
* includes 16 neonates who also received an AED before the start of EEG monitoring.
†For neonates who were administered an AED.
AED, antiepileptic drug;  EEG, electroencephalography; HIE, hypoxic-ischaemic encephalopathy. 
Table 6 Seizure characteristics split by AED group, n=75
received Aed during eeG monitoring 
(n=61)
did not receive Aed during eeG 
monitoring (n=14)
P values*Median (IQr) Median (IQr)
Seizure period (hours)† 22.1 (6.7 to 50.0) 8.0 (0.03 to 15.8) 0.002
Total seizure burden (min) 75.1 (31.2 to 176.8) 33.2 (1.2 to 104.4) 0.030
Number of seizures 28.0 (12.0 to 52.0) 4.5 (1.8 to 20.8) 0.003
Median seizure duration (s) 108.0 (64.5 to 223.0) 113.0 (66.0 to 293.5) 0.849
Maximum hourly seizure burden (min/hour) 23.0 (14.1 to 32.4) 12.1 (1.2 to 29.2) 0.037
*From Mann-Whitney U test.
†Time from start of first EEG seizure to end of last EEG seizure.
AED, antiepileptic drug; EEG, electroencephalography.
seizures reached a peak between 17 (moderate) and 27 (severe) 
hours after birth. Overall, seizures tended to be present for 
longer periods (seizure period) in those with severe HIE. These 
findings confirm the pattern of seizure evolution in HIE, which 
we and others have previously described.14 This information 
is useful clinically; if the evolution is not as expected then an 
alternative diagnosis should actively be considered, and seizures 
which persist beyond 96 hours should be a trigger for additional 
investigations.
In spite of treatment with AEDs, the seizure burden remained 
high with 28% meeting the criteria for neonatal SE, namely 
electrographic seizures continuing for more than half of any 
hour. Neonates with stroke and severe HIE tended to have the 
largest seizure burden. The resistant nature of neonatal seizures 
is shown by the number of AEDs which were given to neonates 
with seizures; 60% of neonates were given more than one type 
of AED and 23% received three or more. A few neonates may 
have responded to the AED administered before monitoring 
started, given that 24 were given an AED before the commence-
ment of cEEG monitoring and then never had an electrographic 
seizure. In 2/24, aEEG monitoring started prior to cEEG moni-
toring. Ictal discharges may have been recognised on the aEEG 
and treated prior to cEEG monitoring.
The collaborators were all experienced users of neonatal 
cEEG and aEEG before the study commenced. Despite this, the 
use of AEDs was not always timely or appropriate, reflecting the 
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Figure 2 Number of seizure episodes and use of antiepileptic drugs (AEDs). The first bar illustrates that 25 neonates experienced one seizure 
episode and of those, 7 neonates had the seizure episode treated appropriately. The third bar illustrates that 12 neonates experienced three seizure 
episodes and of those, 1 neonate had two episodes treated appropriately, 4 neonates had one episode treated appropriately and 7 had none of their 
three episodes treated appropriately.
difficulty in interpretation of EEG round the clock in NICUs. 
Fourteen neonates who had seizures on their cEEG were never 
treated during monitoring, and 27 neonates whose cEEG did not 
ever show seizures were given AEDs while the EEG was running. 
These findings reflect the real-world application of cEEG and 
are likely to be similar in other units. Clinicians are faced with 
having to review many hours of cEEG at a time rapidly, and 
they tend to use the aEEG as a guide to where to interrogate the 
cEEG trace. aEEG is a useful tool which can be used to guide 
treatment,10 but aEEG can be poor at detecting short seizures, 
low voltage seizures and seizures which do not generalise.15 16 In 
addition, although all centres were experienced in using EEG, 
each had their own protocol for reviewing the aEEG. There 
are no definitive guidelines about how regularly cEEG or aEEG 
should be reviewed in neonates at risk of seizures.
The most common artefacts seen in the EEG are those due 
to respiration, ECG, sweat and patting, and these can be diffi-
cult for clinicians to identify.17 Although experts generally agree 
regarding the interpretation of a formal EEG, some seizure 
patterns are very difficult even for experts to recognise.18
Despite the fact that real-time cEEG monitoring was ongoing, 
when AEDs were given, they were not often given within 1 hour 
of an electrographic seizure occurring on the cEEG. Of the 221 
seizure episodes which were captured, on only 24 (11%) of the 
occasions was an AED given within a 1 hour of seizure onset, 
suggesting that in clinical practice seizures are not recognised 
at the time they occur even when cEEG monitoring is in place. 
A further reason may be the time taken to prescribe, obtain and 
administer AEDs. It is not known if treating seizures promptly, if 
an effective treatment can be found, has the potential to reduce 
the TSB but is clearly an area for future research. This is also an 
area where clinical support tools such as seizure detection algo-
rithms may help.2 These algorithms may not be perfect but can 
alert clinical teams when suspicious EEG activity occurs so that 
the cEEG is reviewed as soon as possible.
This study has a number of limitations. First, even though 
seizures were annotated by a group of board-certified electro-
encephalographers with specific experience in neonatal EEG, 
each EEG was not annotated by all four. Therefore, we do not 
have data on inter-rater agreement. However, we and others 
have previously shown that agreement for neonatal EEG seizure 
identification between expert reviewers is very high.18 Second, 
review of cEEG at each site was ad hoc and dependent on the 
individual neonate. There are no protocols in place for review 
of cEEG at any site as neurophysiology services are not avail-
able 24/7. Clinicians request review when concerns are raised on 
EEG or clinically for signs of seizures.
Third, while protocols do exist for the type of first-line, 
second-line and third-line AEDs to be used for the treatment 
of neonatal seizures, the recommended timing of administration 
of the AED is never stipulated. This is largely due to the fact 
that this detailed information has never been available before, 
that is, detailed EEG seizure information. In the absence of any 
clear guidelines for the optimal timing of AED administration, 
we arbitrarily expected that seizures should be treated within 
1 hour of onset in order to be considered as having been appro-
priately treated. We applied this definition consistently to each 
EEG from each infant.
COnClusIOn
Retrospective review of cEEG recordings in six European NICUs 
revealed a high seizure burden in many neonates, irrespective of 
aetiology. Neonatal seizures generally begin early after birth in 
full-term neonates, persist for several days and remain relatively 
resistant to multiple AEDs. Despite the availability of both cEEG 
and aEEG in our centres, many seizures were not treated and 
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other non-seizure events were treated with AEDs. Only 11% of 
all electrographic seizure episodes were treated within 1 hour 
of onset. This highlights the difficulties encountered in inter-
preting the neonatal EEG in real time in the NICU. There is an 
urgent need for automated decision support tools to help detect 
neonatal seizures so that they can be treated more accurately and 
promptly.
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